Labor/HHS/Education Appropriations FY 11, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Duration: January 1, 2008
to
February 28, 2011
General Issues: Budget/Appropriations , Health Issues , Medicare/Medicaid
Spending: about $615,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate, Office of Management & Budget (OMB)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2011
ALPINE GROUP, INC. terminated an engagement in which they represented MEDIMMUNE on April 18, 2011.
Original Filing: 300367549.xml
Lobbying Issues
Labor/HHS/Education Appropriations FY 11, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on Jan. 11, 2011.
Original Filing: 300345495.xml
Lobbying Issues
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, American Workers, State and Business Act of 2010, expansion of Medicaid rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 11, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on Oct. 7, 2010.
Original Filing: 300317811.xml
Lobbying Issues
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, American Workers, State and Business Act of 2010, expansion of Medicaid rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 11, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on July 20, 2010.
Original Filing: 300300218.xml
Lobbying Issues
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4213, American Workers, State and Business Act of 2010, expansion of Medicaid rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 11, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on April 12, 2010.
Original Filing: 300263033.xml
Lobbying Issues
HR 1548, Pathway for Biosimilars Act
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 904, Medicaid Prescription Drug Rebate Equalization Act of 2009, provisions extending drug rebate to managed Medicare plans
H.R. 3590, Patient Protection and Affordable Care Act, provisions extending drug rebate to managed Medicaid plans
H.R. 3962, Affordable Health Care for America Act, provisions extending drug rebate to managed Medicaid plans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 10, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on Jan. 11, 2010.
Original Filing: 300233325.xml
Lobbying Issues
HR 1548, Pathway for Biosimilars Act
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 904, Medicaid Prescription Drug Rebate Equalization Act of 2009, provisions extending drug rebate to managed Medicare plans
H.R. 3590, Patient Protection and Affordable Care Act, provisions extending drug rebate to managed Medicare plans
H.R. 3962, Affordable Health Care for America Act, provisions extending drug rebate to managed Medicare plans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 10, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on Oct. 9, 2009.
Original Filing: 300214979.xml
Lobbying Issues
Implementation of HR 1548, Pathway for Biosimilars Act
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 904, Medicaid Prescription Drug Rebate Equalization Act of 2009, provisions extending drug rebate to managed Medicare plans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 10, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on July 14, 2009.
Original Filing: 300183208.xml
Lobbying Issues
Implementation of HR 1548, Pathway for Biosimilars Act
Passage of H.R. 2596, No Child Left Unimmunized Against Influenza Act of 2009
Passage of S. 953, Seasonal Influenza and Pandemic Preparations Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 904, Medicaid Prescription Drug Rebate Equalization Act of 2009, provisions extending drug rebate to managed Medicare plans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Appropriations FY 10, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on April 16, 2009.
Original Filing: 300151061.xml
Lobbying Issues
Implementation of HR 1548, Pathway for Biosimilars Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 2/S. 275, Children's Health Insurance Program Reauthorization Act of 2009, provisions related to Medicare's quality measures for premature infants
HR 904, Medicaid Prescription Drug Rebate Equalization Act of 2009, provisions extending rebate to managed Medicare plans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Labor/HHS/Education Apppropriations FY 09, funding for state based flu vaccine
Labor/HHS/Education Apppropriations FY 09, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on Jan. 7, 2009.
Original Filing: 300122655.xml
Lobbying Issues
HR 2900, Food and Drug Administration Amendments Act of 2007, provisions dealing with drugs and biologicals
S. 1082, Prescription Drug User Fee Amendment Act of 2007, provisions relating to drugs and biologicals
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 3162, The Children's Health and Medicare Protection Act of 2007, provisions dealing with Medicaid quality measures.
Senate SCHIP legislation
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 3043, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine
S.1710, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on Oct. 10, 2008.
Original Filing: 300101594.xml
Lobbying Issues
HR 2900, Food and Drug Administration Amendments Act of 2007, provisions dealing with drugs and biologicals
S. 1082, Prescription Drug User Fee Amendment Act of 2007, provisions relating to drugs and biologicals
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 3162, The Children's Health and Medicare Protection Act of 2007, provisions dealing with Medicare quality measures.
Senate SCHIP legislation
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 3043, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine
S.1710, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $50,000. The report was filed on July 14, 2008.
Original Filing: 300066130.xml
Lobbying Issues
HR 2900, Food and Drug Administration Amendments Act of 2007, provisions dealing with drugs and biologicals
S. 1082, Prescription Drug User Fee Amendment Act of 2007, provisions relating to drugs and biologicals
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 3162, The Children's Health and Medicare Protection Act of 2007, provisions dealing with Medicare quality measures.
Senate SCHIP legislation
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 3043, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine
S.1710, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, ALPINE GROUP, INC. lobbied for MEDIMMUNE , earning $45,000. The report was filed on April 18, 2008.
Original Filing: 300044050.xml
Lobbying Issues
HR 2900, Food and Drug Administration Amendments Act of 2007, provisions dealing with drugs and biologicals
S. 1082, Prescription Drug User Fee Amendment Act of 2007, provisions relating to drugs and biologicals
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
HR 3162, The Children's Health and Medicare Protection Act of 2007, provisions dealing with Medicare quality measures.
Senate SCHIP legislation
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 3043, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine
S.1710, Labor/HHS/Education Apppropriations FY 08, funding for state based flu vaccine programs
Funding for Vaccine for Children program
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...